Sagimet Biosciences Inc. (SGMT)

Market Cap	174.00M +40.4%
Revenue (ttm)	n/a
Net Income	-51.04M
EPS	-1.58
Shares Out	32.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,561
Open	5.31
Previous Close	5.32
Day's Range	5.25 - 5.38
52-Week Range	1.73 - 11.41
Beta	3.21
Analysts	Strong Buy
Price Target	26.38 (+394.01%)
Earnings Date	May 7, 2026

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMT
• Website: https://www.sagimet.com

Analyst Summary

According to 8 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $26.38, which is an increase of 394.01% from the latest price.

Price Target

$26.38

(394.01% upside)

Analyst Consensus: Strong Buy